Highlights Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Delayed Nasdaq Other stock markets 10:38:35 15/05/2024 pm IST			5-day change	1st Jan Change
0.7296 ^USD	-68.14%		-69.14%	-77.25%

02:16pm	Top Premarket Decliners	MT
02:15pm	Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Decliners	05:46pm	MT
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	30/04	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	15/03	MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	07/02	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11	CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review	31/23/31	CI
Virpax Forms New Unit Novvae Pharmaceuticals	19/23/19	MT
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals	18/23/18	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method	10/23/10	CI
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate	13/23/13	MT
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22	CI
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data	13/23/13	RE
Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology	13/23/13	CI
Virpax Pharmaceuticals Says it has Received Pre-IND Application Guidance From the US FDA on NobrXiol's Development	14/22/14	MT
Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)	14/22/14	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Highlights

Filters